HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

62.000

-1.200-1.90%

Volume:1.11M

Turnover:68.57M

Market Cap:12.34B

PE:-43.83

High:63.300

Open:63.200

Low:61.000

Close:63.200

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.53

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.414

ROE:-51.55%

ROA:-12.87%

PB:11.34

PE(LYR):-43.83

PS:49.50

Loading ...

Overview Company News Filings

LEADS BIOLABS-B (09887) Sees HK$669 Million in Deposited Securities; Major Shareholder Moves 9.71 Million Shares to Morgan Stanley HK

LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained

Leads Biolabs Records Stable Share Structure in August 2026; Public Float Fully Compliant

Bulletin Express

Movement Alert｜LEADS BIOLABS-B Falls 5.05% in Regular Trading, Interim Net Loss Widens Over 33% Year-on-Year

LEADS BIOLABS-B (09887) Announces Interim Results: Net Loss Widens 33.38% to Approximately RMB 222 Million

Nanjing Leads Biolabs FY26 H1 Loss Widens 33.4% to RMB 221.93 Million; Revenue Swings to RMB 35.97 Million

Nanjing Leads Biolabs Co Ltd - Hy Loss Attributable Rmb221.9 Mln

THOMSON REUTERS

Movement Alert｜LEADS BIOLABS-B Falls 5.03% in Regular Trading, Trading at HK$70.85

Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug

Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

THOMSON REUTERS

Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage

Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage

LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase

Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial

Bulletin Express

Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy

THOMSON REUTERS

Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody

Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC

Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec

THOMSON REUTERS

Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/09887/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":62,"timestamp":1789027724007,"preClose":63.2,"halted":0,"volume":1112700,"delay":0,"changeRate":-0.018987341772151944,"floatShares":198000000,"shares":199000000,"eps":-1.4144688225330906,"marketStatus":"Closed","change":-1.2,"latestTime":"09-10 16:08:44","open":63.2,"high":63.3,"low":61,"amount":68573175,"amplitude":0.036392,"askPrice":62,"askSize":2000,"bidPrice":61.95,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-1.6097496867825103,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":63.2,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0.527291,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.414469,"volumeRatio":0.527291,"shares":199000000,"dividePrice":0,"high":63.3,"amplitude":0.036392,"preClose":63.2,"low":61,"week52Low":44.72,"pbRate":"11.34","psRate":"49.50","week52High":97.5,"institutionHeld":0,"latestPrice":62,"committee":-0.666667,"eps":-1.4144688225330906,"divideRate":0,"volume":1112700,"delay":0,"ttmEps":-1.6097496867825103,"open":63.2,"prevYearClose":51,"prevWeekClose":64,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":67.7,"twentyDayClose":69.15,"sixtyDayClose":55.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.6667,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1780070400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-09","current":-38.501919,"percent":0.554348,"low":-76.458084,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"high":-30.202688,"avg":-42.101948,"sd":9.707299,"marketCap":12331685120},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-09","current":-39.527571,"twenty":-45.565149,"median":-39.965338,"eighty":-34.758603,"marketCap":12331685120}],"updateTime":1789030062036},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1119471164","title":"LEADS BIOLABS-B (09887) Sees HK$669 Million in Deposited Securities; Major Shareholder Moves 9.71 Million Shares to Morgan Stanley HK","url":"https://stock-news.laohu8.com/highlight/detail?id=1119471164","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119471164?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:08","pubTimestamp":1788484095,"startTime":"0","endTime":"0","summary":"A recent filing with the Hong Kong Stock Exchange revealed a notable position change for LEADS BIOLABS-B (09887) on September 3rd. The company's total deposited market value reached HK$669 million,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","161027","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180112319","title":"LEADS BIOLABS-B's Price Target Raised to HK$116.9 by CLSA, Outperform Rating Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=1180112319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180112319?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:12","pubTimestamp":1788340334,"startTime":"0","endTime":"0","summary":"CLSA has released a research report indicating that LEADS BIOLABS-B (09887) generated collaboration revenue of RMB 36 million in the first half of the year. The firm anticipates a key catalyst from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EWH","09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102176356","title":"Leads Biolabs Records Stable Share Structure in August 2026; Public Float Fully Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1102176356","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102176356?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:02","pubTimestamp":1788339763,"startTime":"0","endTime":"0","summary":"For the month ended 31 August 2026, Nanjing Leads Biolabs Co., Ltd. reported no movements in either authorised or issued share capital, underscoring a steady equity base throughout the period....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136017385","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.05% in Regular Trading, Interim Net Loss Widens Over 33% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1136017385","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136017385?lang=en_us&edition=fundamental","pubTime":"2026-09-01 14:12","pubTimestamp":1788243139,"startTime":"0","endTime":"0","summary":"On September 1, LEADS BIOLABS-B fell 5.05% in regular trading, trading at HK$68.55/share, with turnover of HK$143 million. The decline came after the company released its interim results on August...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LEADS BIOLABS-B Drops as Net Loss Widens 33%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161064979","title":"LEADS BIOLABS-B (09887) Announces Interim Results: Net Loss Widens 33.38% to Approximately RMB 222 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1161064979","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161064979?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:40","pubTimestamp":1788165619,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has unveiled its interim results for the 2026 fiscal year, recording revenue of RMB 35.969 million. Research and development expenses surged by 44.92% year-on-year to...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073726","title":"Nanjing Leads Biolabs FY26 H1 Loss Widens 33.4% to RMB 221.93 Million; Revenue Swings to RMB 35.97 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073726","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073726?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:32","pubTimestamp":1788165161,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs FY26 H1 loss widens 33.4% to RMB 221.93 million; revenue swings to RMB 35.97 millionNanjing Leads Biolabs posted revenue of RMB 35.97 million, compared with no revenue a year ear","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL9ZD8wg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663073742","title":"Nanjing Leads Biolabs Co Ltd - Hy Loss Attributable Rmb221.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073742?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:32","pubTimestamp":1788165150,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R04X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161283999","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.03% in Regular Trading, Trading at HK$70.85","url":"https://stock-news.laohu8.com/highlight/detail?id=1161283999","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161283999?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:59","pubTimestamp":1787727540,"startTime":"0","endTime":"0","summary":"On August 26, LEADS BIOLABS-B fell 5.03% in regular trading, trading at HK$70.85/share, with turnover of HK$111 million.Within the Biotechnology sector where LEADS BIOLABS-B belongs, peer stocks...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662531786","title":"Nanjing Leads Rises on Clinical Study Progress on Cancer Treatment Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2662531786","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662531786?lang=en_us&edition=fundamental","pubTime":"2026-08-25 13:43","pubTimestamp":1787636594,"startTime":"0","endTime":"0","summary":"BUZZ-Nanjing Leads rises on clinical study progress on cancer treatment drug** Shares of Nanjing Leads Biolabs9887.HKjump 9.2% to HK$75.4, their biggest intraday pct gain since July 15** The China-based oncology and autoimmune therapies developer says Phase II clinical study of its drug candidate LBL-024 as a first-line treatment for patients with metastatic esophageal squamous cell carcinoma has completed the safety lead-in stage and has advanced to the combination treatmentexpansion stage** LBL-024 has demonstrated a favourable safety and tolerability profile in about 800 patients treated to date, supporting its development as a potential next-generation immuno-oncology backbone therapy, says Nanjing Leads** YTD, stock up 46.2%, Hang Seng Biotech Index.HSBIOup 11.5%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M047:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200258","title":"Leads Biolabs Advances Opamtistomig Phase II First-Line ESCC Trial into Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200258","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662200258?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624721,"startTime":"0","endTime":"0","summary":"Leads Biolabs advances Opamtistomig Phase II first-line ESCC trial into expansion stageNanjing Leads Biolabs moved its Phase II study of Opamtistomig into an expansion stage for first-line esophageal ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL2FJpxz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","HK0000252160.HKD","NDAQ","SG9999014039.USD","SG9999014021.USD","SG9999014013.SGD","LU2095319765.USD","BK4112","HK0000500386.USD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","09887","IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014005.SGD","HK0000252152.HKD","IE00BQXX3C00.GBP","BK1161","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662004752","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Phase Ii Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=2662004752","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662004752?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:25","pubTimestamp":1787624702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA7XQSTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131567775","title":"Hong Kong Stock Flash | LEADS BIOLABS-B (09887) Surges Over 5% in Morning Trade as Phase II Trial for First-Line ESCC Advances to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131567775","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131567775?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:16","pubTimestamp":1787624183,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) shares climbed more than 5% during Tuesday morning trading, last up 4.42% at HK$72.10 with turnover reaching HK$33.55 million.The company announced that its self-developed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","HK0000252152.HKD","KCAI","BK4585","HK0000252160.HKD","BK1161","BK4588","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163673761","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.14% in Regular Trading, Phase II ESCC Study Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1163673761","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163673761?lang=en_us&edition=fundamental","pubTime":"2026-08-25 09:55","pubTimestamp":1787622946,"startTime":"0","endTime":"0","summary":"On August 25, LEADS BIOLABS-B rose 5.14% in regular trading, trading at HK$72.4/share, with turnover of approximately HK$28.4 million. The stock gained on news that its core drug candidate Vilixin...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"LEADS BIOLABS-B Surges on Vilixin ESCC Phase II Expansion","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121426329","title":"LEADS BIOLABS-B (09887) Expands Phase II Study of Vilitrin (Opasotiumumab, PD-L1/4-1BB Bispecific Antibody, LBL-024) as First-Line Treatment for ESCC into Extension Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=1121426329","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121426329?lang=en_us&edition=fundamental","pubTime":"2026-08-25 07:00","pubTimestamp":1787612419,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the Phase II clinical study of its self-developed investigational drug Vilitrin (Opasotiumumab, a PD-L1/4-1BB bispecific antibody, LBL-024) for the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","HK0000252152.HKD","HK0000500386.USD","09887","PD","BK1161","LU1169590202.USD","HK0000252160.HKD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174574289","title":"Leads Biolabs Advances PD-L1/4-1BB Bispecific Antibody LBL-024 into Expansion Phase of Phase II First-Line ESCC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1174574289","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174574289?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:46","pubTimestamp":1787611599,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed bispecific antibody LBL-024 (Opamtistomig) has completed the safety lead-in portion of a Phase II study in first-line...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326621","title":"Leads Biolabs' Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Nda Accepted by Nmpa, Poised to Become World's First Approved 4-1Bb-Targeting Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326621","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661326621?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:21","pubTimestamp":1787304089,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148838562","title":"Leads Biolabs-B Submits NDA for Velixin with NMPA, a Potential First-in-Class PD-L1/4-1BB Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1148838562","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148838562?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:50","pubTimestamp":1787302229,"startTime":"0","endTime":"0","summary":"Leads Biolabs-B (09887) has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has formally accepted the company's independently developed...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","IPOS","LU1169589451.USD","HK0000252160.HKD","BK4023","PD","HK0000500386.USD","LU1169590202.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661655402","title":"Nanjing Leads Biolabs Says NMPA Accepts NDA for LBL-024 in Advanced EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2661655402","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661655402?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301756,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NECNanjing Leads Biolabs’ NMPA drug review center accepted an NDA for LBL-024 (Opatlisumab), a PD-L1/4-1BB bispecific, in EP-NEC.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDLc4nHQt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265547","title":"Nanjing Leads Biolabs Co - Nmpa Accepts Nda for Lbl-024 (Opamtistomig) for Advanced Ep-Nec","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265547","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661265547?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:42","pubTimestamp":1787301730,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0E0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160907287","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.65% in Regular Trading, Trading at HK$71.95","url":"https://stock-news.laohu8.com/highlight/detail?id=1160907287","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160907287?lang=en_us&edition=fundamental","pubTime":"2026-08-21 09:43","pubTimestamp":1787276590,"startTime":"0","endTime":"0","summary":"On August 21, LEADS BIOLABS-B fell 5.65% in regular trading, trading at HK$71.95/share, with turnover of HK$29.23 million.Within the Biotechnology sector where LEADS BIOLABS-B belongs, the sector...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":133,"code":"91000000","status":"200"}]}}